Highest-materiality recent filing
PMV Pharma Q1 net loss $18M; rezatapopt NDA for ovarian cancer targeted for Q1 2027
Cash and securities $93.5M at March 31, 2026; net cash used in operations $19.7M for Q1.
PMV Pharma reports FY2025 net loss of $77.7M; reaffirms NDA filing for rezatapopt in Q1 2027
Cash and securities $112.9M at Dec 2025 (down from $183.3M); runway to end of Q2 2027.
PMV Pharma reports Q3 2025 net loss of $21.1M; highlights 34% ORR with rezatapopt in PYNNACLE study
Cash, cash equivalents, and marketable securities of $129.3M as of Sept 30, 2025; cash runway to end of Q1 2027.
Overall ORR 33% (32/97 evaluable patients) across 8 tumor types; median duration of response 6.2 months.
PMV Pharma Q2 net loss $21.2M; cash $148.3M; Phase 2 interim analysis webinar Sept 10
Net loss $21.2M for Q2 2025 vs $1.2M in Q2 2024, due to prior-year $16.2M tax benefit from NOL sale.
PMV Pharma Q1 net loss $17.5M; Phase 2 interim data expected mid-2025
Phase 2 PYNNACLE interim analysis mid-2025; data for ~50 patients with ≥18 weeks follow-up.
Net loss of $58.7M for FY2024, compared to $69.0M in FY2023; no revenue.
PMV Pharma Q3 net loss $19.2M; cash runway to end 2026; Phase 2 enrollment on track
Net loss $19.2M in Q3 2024 vs $16.6M Q3 2023; R&D spend rose to $16.9M on trial costs.
PMV Pharma Q2 net loss $1.2M on $16.2M tax benefit; cash $212.9M; PYNNACLE Phase 2 on track
Net loss narrowed to $1.2M from $17.4M YoY due to $16.2M income tax benefit from NOL sale.
PMV Pharma Q1 loss narrows to $15.3M; Phase 2 PYNNACLE trial initiated
Net loss $15.3M vs $19.1M YoY; cash $213.1M, expected runway to end of 2026.
PMV Pharma FY 2023 net loss $69.0M; rezatapopt Phase 2 on track for Q1 2024
Cash, cash equivalents, and marketable securities $228.6M at Dec 31, 2023; cost savings from workforce reduction extend runway to end 2026.
PMV Pharma cuts workforce 30%, extends cash runway to end of 2026
Workforce reduction of ~30% to prioritize PC14586 development and streamline operations.
PMV Pharma appoints new CFO, CMO departs; leadership reshuffled as late-stage program advances
Michael Carulli promoted to CFO; Winston Kung transitions to advisor through March 2024.
PMV Pharma reports Q3 loss, PC14586 Phase 1 data shows 38% ORR at RP2D
Net loss 9mo $53.2M vs $54.0M YoY; cash $238.1M as of Sep 30, 2023.
PMV Pharma: PC14586 Phase 1 shows 38% ORR at RP2D; registrational Phase 2 planned early 2024
Confirmed ORR 38% (6/16) at RP2D 2000 mg daily in TP53 Y220C/KRAS wild-type patients; median DoR 7 months.
PMV Pharma to present updated Phase 1 PC14586 data at AACR-NCI-EORTC; KOL webinar planned
Updated Phase 1 data cutoff Sep 5, 2023; abstract with May 1 cutoff published.
PMV Pharma Q2 net loss $17.4M; FDA aligns on Phase 2 dose for PC14586
Cash, equivalents & marketable securities $218.8M as of June 30, 2023, down from $277.4M a year ago.
PMV Pharma reports FY2022 net loss $73.3M; cash $243.5M; PC14586 update expected 2H 2023
Net loss $73.3M in FY2022 vs $57.8M in FY2021; R&D expenses rose to $52.0M from $36.5M.
PMV Pharma Q3 2022 net loss widens to $54M; cash at $258.9M; PC14586 trial ongoing
Net loss for nine months ended Sep 30, 2022: $54.0M vs $39.5M YoY; cash & equivalents $258.9M (Dec 2021: $314.1M).
PMV Pharma Q2 net loss $35.7M; cash $277.4M; PC14586 combo with KEYTRUDA planned
Net loss for H1 2022: $35.7M vs $24.5M YoY; cash, cash equivalents and marketable securities $277.4M as of June 30, 2022.
PMV Pharma reports PC14586 Phase 1 data: 32% ORR at high doses, responses in 6 tumor types
Overall response rate (ORR) 32% (8/25) in patients receiving daily dose ≥1150 mg; 24% (8/33) across all doses.
PMV Pharma's PC14586 shows 30% partial response in higher dose cohorts at ASCO
Abstract reports 3/10 (30%) partial responses in patients treated in higher dose cohorts of Phase 1/2 PYNNACLE trial.
PMV Pharma Q3 2021 net loss $39.5M for nine months; cash $326.3M
Net loss for nine months ended Sep 30, 2021: $39.5M vs $24.0M in prior-year period.
PMV Pharma enters $150M ATM equity distribution agreement with Jefferies
Open Market Sale Agreement with Jefferies LLC for up to $150M in gross proceeds from common stock sales.
On January 5, 2024, the Company also announced that Winston Kung, the Company’s current Chief Operating Officer (“ COO ”) and CFO, will transition from his role as COO and CFO, effective January 4, 2024.
Also on January 5, 2024, the Company announced that Leila Alland, M.D., the Company’s Chief Medical Officer (“ CMO ”), will transition from her role as CMO, effective on January 5, 2024.
On January 5, 2024, PMV Pharmaceuticals, Inc. (the “ Company ”) announced the appointment of Michael Carulli as Chief Financial Officer (“ CFO ”), principal financial officer and principal accounting officer of the Company
On November 3, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of the Company unanimously approved the appointment of Carol Gallagher, Pharm.D. as a Class I director of the Company to fill the vacancy of Dr. Schroeder’s seat on the Board of the Company.
On November 3, 2022, Thilo Schroeder, Ph.D., notified PMV Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors (the “Board”), which resignation was effective on that date.
On January 5, 2022, Peter Thompson, M.D. notified PMV Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors (the “Board”), which resignation was effected on January 5, 2022.
On January 5, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of the Company unanimously approved the appointment of Kirsten Flowers as a director and Class I director of the Company to fill the vacancy of Dr. Thompson’s seat on the Board of the Company.
Max materiality 0.85 · Median 0.60 · Most common event earnings